Please login to the form below
Vaccine
This page shows the latest Vaccine news and features for those working in and with pharma, biotech and healthcare.
Positive results for GSK/CureVac’s COVID-19 vaccine
second-generation vaccine candidates that offer improved immune responses and target emerging variants. ... Combined with lower doses, these second-generation vaccines could also enable broad protection against selected strains in a multivalent vaccine
Latest news
-
Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments
Continued need for vaccines/treatments 'likely' as world moves into the next phase of the pandemic. ... The company is expecting revenue from its COVID-19 vaccine to reach approximately $26bn for 2021 alone.
-
Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
The vaccine has been authorised in the US for 12- to 15-year-olds. ... The vaccine was also well tolerated, with side effects in this study found to be ‘generally consistent’ with those seen in participants aged 16 to 25.
-
Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
Company says removing IP protections would make it ‘harder’ to make vaccines in the short term. ... vaccine.”. “Greater demand pressures on inputs from new market entrants will make it harder, not easier, to manufacture COVID-19 vaccines in the
-
EMA introduces new measures to enable flexibility for non-COVID-19 procedures
This has caused the EMA’s resources to become ‘highly focused’ on reviewing COVID-19 vaccines and therapeutics, while also ensuring these medicines have met ‘rigorous safety’ standards. ... Among these measures are new procedures enabling all
-
Novavax announces further delays for regulatory filings of COVID-19 vaccine
Based on this information, Novavax calculated that its vaccine is 95.6% effective against the original COVID-19 strain and 85.6% effective against the UK variant. ... Peak capacity for the vaccine is expected in the fourth quarter, which will support 150
Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments
Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
EMA introduces new measures to enable flexibility for non-COVID-19 procedures
Novavax announces further delays for regulatory filings of COVID-19 vaccine
More from news
Approximately 178 fully matching, plus 1,380 partially matching documents found.
Latest Intelligence
-
The new reality of building a corporate brand in pharma
Until the likes of Pfizer, AstraZeneca and Moderna started to have their coronavirus vaccines approved, the companies behind the medicines were rarely recognised by the public. ... Has anyone ever paid attention to – or asked – who produced their
-
Now that COVID-19 vaccines have been approved, it’s our turn, healthcare communicators
National and governmental bodies are already taking action to increase public understanding of the role of pharma in vaccine development and the value that vaccines bring (eg, ). Additionally, medical professional bodies ... A range of single-dose
-
Setting up for success in a post-Brexit, post-pandemic Britain
With society and business continuing to face a seemingly relentless stream of restrictions, national lockdowns, a worldwide race to find and now roll out the new COVID-19 vaccines, not to ... In many ways, vaccine innovations have improved the reputation
-
A cultural shift in clinical research
But while unprecedented feats were achieved in clinical research for COVID-19 treatments and vaccines, many other projects were halted and patient recruitment stopped entirely. ... By contrast, the discovery and development of multiple successful
-
AI and accelerated computing ring in new era for healthcare
molecules – such as the spike proteins on the COVID-19 virus – and accelerate drug and vaccine discovery. ... to solve large-scale problems and improve patient care, diagnosis and delivery of critical medicines and vaccines.
The new reality of building a corporate brand in pharma
Now that COVID-19 vaccines have been approved, it’s our turn, healthcare communicators
Setting up for success in a post-Brexit, post-pandemic Britain
A cultural shift in clinical research
AI and accelerated computing ring in new era for healthcare
More from intelligence
Approximately 6 fully matching, plus 124 partially matching documents found.
Latest appointments
-
ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
In this role, he oversaw all media relations for the UK’s COVID-19 vaccination programme, providing strategic advice to Vaccines Minister Nadhim Zahawi and Health and Social Care Secretary Matt
-
Virtual agency The Difference Collective makes new hires to senior team
Hornby has led communications for the UK government’s Vaccine Taskforce and previously led media and communications for GlaxoSmithKline.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Over the course of his most recent stint at Merck, the company has achieved over 100 regulatory approvals for its medicines and vaccines globally. ... As a result of Roger’s hands-on and inspirational leadership, MRL is well positioned to bring forward
-
Evoke KYNE promotes Dante DelVecchio to senior VP
In his new role, he will become a member of the firm’s senior management team, and will continue to oversee key client engagements in infectious diseases, vaccines and immuno-oncology.
-
New hires at Bayer, Eisai and Accord Healthcare
Most recently, she held the position of vice president of M&A operations and divestitures and led the infectious diseases and vaccines business development. ... She joins Eisai from Merck, where she served as executive director, clinical quality assurance
ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
Virtual agency The Difference Collective makes new hires to senior team
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Evoke KYNE promotes Dante DelVecchio to senior VP
New hires at Bayer, Eisai and Accord Healthcare
More from appointments
Approximately 5 fully matching, plus 66 partially matching documents found.
Latest from PMHub
-
Are you ready for the digital health revolution?
With vaccines and new treatments providing light at the end of the tunnel, the question now is whether the remote solutions that got us through the pandemic are here to stay,
-
The unheard, unseen, and uncorrected effects of COVID-19
groups, and to understand whether this hindered people’s willingness to participate in COVID-19 vaccine clinical trials. ... This can be seen by the lack of willingness of Black participants to take part in COVID-19 vaccine trials — 94.3% of surveyed
-
Fear or encouragement, which is best to drive behaviour change?
But timing is everything with this strategy, and I would say that the government have been extremely lucky with the timing of the vaccine, as they have been able to provide
-
When Will We Be Back To Normal?
And it did. It is impossible to understate what a phenomenal achievement the vaccine programs against COVID-19 have been.
-
Preparing Science for the Real World
Recent communications around the various COVID-19 vaccine studies have highlighted the rate at which data are digested, interpreted, and re-published in multiple forms and forums. ... At best, it has a negative impact on trust in the clinical evaluation
The unheard, unseen, and uncorrected effects of COVID-19
When Will We Be Back To Normal?
Preparing Science for the Real World
More from PMHub
Approximately 12 fully matching, plus 76 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Publications Director
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Senior Account Executive
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Senior Medical Writer
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Medical Editor
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Origins Insights
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
